Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7235823 | 0.85 | HPGD (0.44) | HPGDALDH1A1MEN1POLBRAB9A | |
| SCHEMBL4787012 | 0.84 | HDAC1 (0.61) | HPGDALDH1A1RAB9AKDM4EHPGDS | |
| SCHEMBL6359855 | 0.81 | DYRK1A (0.51) | HPGDALDH1A1RAB9AKDM4EHPGDS | |
| SCHEMBL7236771 | 0.80 | KDM4E (0.51) | HPGDALDH1A1MEN1RAB9AKMT2A | |
| SCHEMBL6353641 | 0.78 | CDC25B (0.50) | HPGDALDH1A1RAB9AKMT2ATDP1 | |
| SCHEMBL13707355 | 0.78 | CA12 (0.47) | HPGDALDH1A1POLBTDP1KDM4E | |
| SCHEMBL6487879 | 0.77 | HPGD (0.67) | HPGDALDH1A1MEN1POLBRAB9A | |
| SCHEMBL11523983 | 0.77 | CA12 (0.51) | HPGDALDH1A1MEN1POLBRAB9A | |
| SCHEMBL1761545 | 0.76 | RAB9A (0.92) | HPGDALDH1A1MEN1POLBRAB9A | |
| SCHEMBL2411077 | 0.76 | HPGD (0.70) | HPGDALDH1A1MEN1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202772-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2022-06-30 | — | — | US | disclosed |
| WO-2021050556-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2008101186-A1 | INHIBITORS FOR HDAC8 | THE J. DAVID GLADSTONE INSTITUTES (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008101186-A1 | INHIBITORS FOR HDAC8 | THE J. DAVID GLADSTONE INSTITUTES (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1532134-B1 | NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | AVENTIS PHARMA SA (FR) | 2008-06-04 | — | — | EP | disclosed |
| US-20050209284-A1 | Tec kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| EP-1532134-A1 | NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | Aventis Pharma S.A. (FR) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004007477-A1 | NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | WO | disclosed |
| US-20030055263-A1 | Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-20 | — | — | US | disclosed |
| WO-2003006443-A2 | 2- 4-(NAPHTALIN-2-YL)-THIAZOL-2-YLAMINOCARBONYL BENZOIC ACID AND 2- 4-(NAPHTALIN-2-YL)-PYRIMIDIN-2-YLAMINOCARBONYL BENZOIC ACID AND ADDITIONAL COMPOUNDS SERVING AS TELOMERASE INHIBITORS FOR USE IN TUMOR THERAPY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202772-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS | RACK1, RRBP1, RPL30 | HPGD 3417/4885ALDH1A1 3524/4885MEN1 4218/4885 |
| US-20030055263-A1 | Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production | TERT, POT1, REV1 | HPGD 2265/4885ALDH1A1 13/4885MEN1 386/4885 |
| US-20050209284-A1 | Tec kinase inhibitors | TEC, ITK, TXK | HPGD 3708/4885ALDH1A1 3145/4885MEN1 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.